A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT ID: NCT00705406

Last Updated: 2015-02-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

405 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether peramivir is safe and effective in the treatment of uncomplicated seasonal influenza.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute, Uncomplicated Human Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Peramivir 600 mg

600 mg peramivir administered as bilateral 2-mL intramuscular injection.

Group Type EXPERIMENTAL

Peramivir

Intervention Type DRUG

600 mg peramivir administered as bilateral 2-mL intramuscular injection

Placebo

Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peramivir

600 mg peramivir administered as bilateral 2-mL intramuscular injection

Intervention Type DRUG

Placebo

Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and non-pregnant female subjects age ≥18 years.
* A positive Influenza A or B Rapid Antigen Test (RAT) performed with a commercially available test kit on an adequate anterior nasal specimen, in accordance with the manufacturer's instructions. A negative initial RAT should be repeated within one hour.
* Presence of fever at time of screening of ≥38.0 ºC (≥100.4 ºF) taken orally, or ≥38.5 ºC (≥101.2 ºF) taken rectally. A subject self-report of a history of fever or feverishness within the 24 hours prior to screening will also qualify for enrollment in the absence of documented fever at the time of screening.
* Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of at least moderate severity.
* Presence of at least one constitutional symptom (myalgia \[aches and pains\], headache, feverishness, or fatigue) of at least moderate severity.
* Onset of symptoms no more than 36 hours before presentation for screening.
* Written informed consent.

Exclusion Criteria

* Women who are pregnant or breast-feeding.
* Presence of clinically significant signs of acute respiratory distress
* History of severe chronic obstructive pulmonary disease (COPD) or severe persistent asthma.
* History of heart failure or angina requiring daily pharmacotherapy with symptoms consistent with New York Heart Association Class III or IV functional status within the past 12 months.
* Screening ECG which suggests acute ischemia or presence of medically significant dysrhythmia.
* History of chronic renal impairment requiring hemodialysis and/or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance \<50 mL/min).
* Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset of symptoms of influenza) which, in the investigator's opinion, indicates that such finding(s) could represent complications of influenza.
* Current clinical evidence, including clinical signs and/or symptoms consistent with otitis, bronchitis, sinusitis and/or pneumonia, or active bacterial infection at any body site that requires therapy with oral or systemic antibiotics.
* Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy which would include oral or systemic treatment with \> 10 mg prednisone or equivalent on a daily basis within 30 days of screening.
* Currently receiving treatment for viral hepatitis B or viral hepatitis C.
* Presence of known HIV infection with a CD4 count \<350 cell/mm3.
* Current therapy with oral warfarin or other systemic anticoagulant.
* Receipt of any doses of rimantadine, amantadine, zanamivir, or oseltamivir in the 7 days prior to screening.
* Immunized against influenza with live attenuated virus vaccine (FluMist®) in the previous 21 days.
* Immunized against influenza with inactivated virus vaccine within the previous 14 days.
* Receipt of any intramuscular injection with the previous 7 days.
* History of alcohol abuse or drug addiction within 1 year prior to admission in the study.
* Participation in a previous study of intramuscular or intravenous peramivir or previous participation in this study.
* Participation in a study of any investigational drug or device within the last 30 days.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioCryst Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

West Alabama Research, Inc.

Birmingham, Alabama, United States

Site Status

Greystone Medical Research, LLC

Birmingham, Alabama, United States

Site Status

NextCare Institute for Clinical Research

Phoenix, Arizona, United States

Site Status

Clopton Clinic

Jonesboro, Arkansas, United States

Site Status

NEA Clinic

Jonesboro, Arkansas, United States

Site Status

North Central Arkansas Medical Associates

Mountain Home, Arkansas, United States

Site Status

Impact Clinical Trials

Beverly Hills, California, United States

Site Status

Medcenter

Carmichael, California, United States

Site Status

Center for Clinical Trials, LLC

Paramount, California, United States

Site Status

Coastal Medical Research Group, Inc.

San Luis Obispo, California, United States

Site Status

Alpine Research Center

Boulder, Colorado, United States

Site Status

1st Allergy and Clinical Research Center

Centennial, Colorado, United States

Site Status

Clinical Research of South Florida

Coral Gables, Florida, United States

Site Status

Westside Center for Clinical Research

Jacksonville, Florida, United States

Site Status

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Site Status

University Clinical Research, Inc.

Pembroke Pines, Florida, United States

Site Status

DMI Research, Inc.

Pinellas Park, Florida, United States

Site Status

Wilker/Powers Center for Clinical Studies, d/b/a ProHealth Clinical Studies

Saint Cloud, Florida, United States

Site Status

Southeast Regional Research Group

Columbus, Georgia, United States

Site Status

Southeast Regional Research Group

Savannah, Georgia, United States

Site Status

The Kaufmann Clinic, Inc.

Woodstock, Georgia, United States

Site Status

Idaho Falls Infectious Diseases

Idaho Falls, Idaho, United States

Site Status

Dr. Arthur Davida

Bloomingdale, Illinois, United States

Site Status

Investigators Research Group, LLC

Indianapolis, Indiana, United States

Site Status

Medical Associates Clinic

Dubuque, Iowa, United States

Site Status

Heart of America Research

Shawnee, Kansas, United States

Site Status

Kentucky Lung Clinic

Hazard, Kentucky, United States

Site Status

Gulf Coast Research, LLC

Baton Rouge, Louisiana, United States

Site Status

Acadia Clinical Research

Bangor, Maine, United States

Site Status

Clarksburg Medical Center

Clarksburg, Maryland, United States

Site Status

Miray Medical Center

Brockton, Massachusetts, United States

Site Status

Detroit Receiving Hospital, UHC 6G

Detroit, Michigan, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

KMED Research

Saint Claire Shores, Michigan, United States

Site Status

Olive Branch Family Medical Center

Olive Branch, Mississippi, United States

Site Status

Bozeman Urgent Care Center

Bozeman, Montana, United States

Site Status

Mercury Street Medical Group, PLLC

Butte, Montana, United States

Site Status

Prairie Fields Family Medicine, P.C.

Fremont, Nebraska, United States

Site Status

Impact Clinical Trials, Las Vegas

Las Vegas, Nevada, United States

Site Status

United Medical Associates

Johnson City, New York, United States

Site Status

Twelve Corners Internal Medicine

Rochester, New York, United States

Site Status

Bland Clinic

Greensboro, North Carolina, United States

Site Status

Community Medical Associates, LLC

Canfield, Ohio, United States

Site Status

Advanced Health Care Services, Inc

Thornville, Ohio, United States

Site Status

Urgent Care of Green County, PLLC

Owasso, Oklahoma, United States

Site Status

Integrated Medical Research, PC

Ashland, Oregon, United States

Site Status

Pivotal Clinical Research, LLC

Souderton, Pennsylvania, United States

Site Status

New England Center for Clinical Research, Inc.

Cranston, Rhode Island, United States

Site Status

Notheast Clinical Research

Cumberland, Rhode Island, United States

Site Status

Clinical Partners, LLC

Johnston, Rhode Island, United States

Site Status

Omega Medical Research

Warwick, Rhode Island, United States

Site Status

Hillcrest Clinical Research, LLC

Simpsonville, South Carolina, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

Holston Medical Group

Bristol, Tennessee, United States

Site Status

DiscoveResearch, Inc.

Bryan, Texas, United States

Site Status

Corpus Christi Family Wellness Center, Research Division

Corpus Christi, Texas, United States

Site Status

Allergy/Immunology Research Center of North Texas

Dallas, Texas, United States

Site Status

Towngate Plaza Medical Center

Garland, Texas, United States

Site Status

West Houston Clinical Research

Houston, Texas, United States

Site Status

Texas Medical Research Associates, LLC

San Antonio, Texas, United States

Site Status

Martin Diagnostic Clinic

Tomball, Texas, United States

Site Status

J. Lewis Research, Inc., FirstMed

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc./Foothill Family Clinic South

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc./FirstMed East

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc./Foothill Family Clinic South

Salt Lake City, Utah, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

Dean Medical Center

Oregon, Wisconsin, United States

Site Status

Pacific Medical Centre Blacktown

Blacktown, New South Wales, Australia

Site Status

East Sydney Doctors

Darlinghurst, New South Wales, Australia

Site Status

Symbion Pathology

Hurtsville, New South Wales, Australia

Site Status

Peninsula Medical Centre

Umina, New South Wales, Australia

Site Status

Rivercity Private Hospital Specialist

Auchenflower, Queensland, Australia

Site Status

Caboolture Clinical Research Centre

Caboolture, Queensland, Australia

Site Status

Peninsula Specialist Centre

Kpparing, Queensland, Australia

Site Status

Health Services -University of Melbourne

Carlton, Victoria, Australia

Site Status

Athelstone Medical Clinic

Adelaide, , Australia

Site Status

Trialworks Clinical Research Services

Brisbane, , Australia

Site Status

Dr Doongs Surgery

Burwood, , Australia

Site Status

Holdsworth House Medical Practice

Darlinghurst, , Australia

Site Status

Doctors of Ivanhoe,

Melbourne, , Australia

Site Status

Lung Institute of Western Australia,

Nedlands, , Australia

Site Status

Pitt Street Merrylands Medical Centre

Sydney, , Australia

Site Status

St George's Hospital

Christchurch, Christchurch, New Zealand

Site Status

Bairds Road Family Health Care

Rotorua, Rotorua, New Zealand

Site Status

Greenhithe Medical Centre

Auckland, , New Zealand

Site Status

Southern Clinical Trials Ltd

Christchurch, , New Zealand

Site Status

Caversham Medical Centre

Dunedin, , New Zealand

Site Status

Dr. Gillies

Rotorua, , New Zealand

Site Status

Hinemoa House Family Health Centre

Rotorua, , New Zealand

Site Status

Jsha Research

Bloemfontein, Bloemfontein, South Africa

Site Status

Nortje, MD

Goodwood, Capetown, South Africa

Site Status

Greenbury Medical Centre

Greenbury, Durban, South Africa

Site Status

Sebastian, MD

Silverglen, Durban, South Africa

Site Status

Quinta-Research

Bloemfontein, Free State, South Africa

Site Status

Wilhase, AC

Reigerpark, Gauteg, South Africa

Site Status

NHC Medical Centre

Bryanston, Gauteng, South Africa

Site Status

R. Dulabh, MD

Klipspruit West, Gauteng, South Africa

Site Status

DJW Navorsing

Noordheuwel, Krugersdorp, South Africa

Site Status

Pillay, MD

Verulam, KwaZulu-Natal, South Africa

Site Status

Vawda, Z.FA

Durban, KZ-Natal, South Africa

Site Status

le Clus, MD

Kempton Park, Pretoria, South Africa

Site Status

Sunnyside Medi-Clinic

Sunnyside Pretoria, Pretoria, South Africa

Site Status

Kaapzicht Centre

Cape Town, W. Cape, South Africa

Site Status

Syzygy SMO Intercare Medical and Dental Centre

Cape Town, W. Cape, South Africa

Site Status

Clinical Project Research SA (Pty) Ltd.

Worcester, W. Cape, South Africa

Site Status

Benmed Park Clinic

Benoni, , South Africa

Site Status

Armansis Medical Centre

Brits, , South Africa

Site Status

Cape Clinical Trial, Bishop Lavis Day Hospital

Cape Town, , South Africa

Site Status

First House

Cape Town, , South Africa

Site Status

Synapta Clinical Research Centre

Durban, , South Africa

Site Status

Dr. Janari

Durban, , South Africa

Site Status

Dr. van Rensburg

eManzimtoti, , South Africa

Site Status

Dr. Makan

Johannesburg, , South Africa

Site Status

Newgate Centre

Johannesburg, , South Africa

Site Status

GCT Trials, Mercantile Hospital no 9

Port Elizabeth, , South Africa

Site Status

Dr. Nel

Pretoria, , South Africa

Site Status

Emmed Research

Pretoria, , South Africa

Site Status

Dr. de Bruin

Pretoria, , South Africa

Site Status

Westmed Clinical Trial Centre, Pretoria West Medicross Building

Pretoria, , South Africa

Site Status

Dr. Fouche

Roodepoort, , South Africa

Site Status

Dr. de Villiers

Scottburgh, , South Africa

Site Status

Dr. Bhorat

Soweto, , South Africa

Site Status

Clinical Projects Research SA Ltd

Worcester, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia New Zealand South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HHS 0100200700032C

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

BCX1812-212

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of VIR-2482 in Healthy Volunteers
NCT04033406 COMPLETED PHASE1